SecBot SecBot

EWTX

Edgewise Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001710072 Biotech & Drug Discovery
$43.68 −2.25 (−4.90%)
Nov 16 4:00 PM ET · prev $45.93
Market cap
$5.0B
Mid cap
Consensus
Buy
89% Buy or better · 19 analysts
Median target
$53.50
+22% · range $36.00–85.00
1 year
+96.2%
from $22.26 · Nov 17
30 days
+15.2%
from $37.92
52-week range
$20.94–48.74
−10% from high · low Dec 22
Avg volume 20D
1.72M
Nov 5 spike 5.22M
Short interest
12.70M
≈11.6% of shares · +8.0%
Days to cover
9.6
at average volume
Insider net
−$10.0M
0 buyers · 6 sellers · since Jun 5
New fund stakes
1
Q2 2026 13F · 2 exits
Filing reports
14
analyzed by SecBot
SecBot read MIXED 5 reports · 90 days
Balance 0 bearish · 0 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 2/5

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    6 insiders sold $10.0M.

  • InstitutionsBULLISH

    Q2 2026: 26 added (1 new), 12 trimmed or exited. Largest new: Adage Capital Partners Gp, L.L.C $18.8M.

  • AnalystsBULLISH

    17 of 19 rate it Buy or better. Median target $53.50 (+22%).

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.379 → −$0.442 over 90 days. 2 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +8.0% to 12.70M shares. 9.6 days to cover, ≈11.6% of shares.

  • TrendUPTREND

    6% above its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
2
exits
$18.8M
in new stakes
FundMoveSharesValue
FMR LLCDOUBLED5,489,135$223.0M
BAKER BROS. ADVISORS LPTRIM3,701,719$150.4M
Qube Research & Technologies LtdADD1,252,507$50.9M
PRICE T ROWE ASSOCIATES INC /MD/DOUBLED816,518$33.2M
VANGUARD PORTFOLIO MANAGEMENT LLCADD786,456$32.0M
NORGES BANKTRIM510,140$20.7M
ADAGE CAPITAL PARTNERS GP, L.L.C.NEW462,000$18.8M
RAYMOND JAMES FINANCIAL INCDOUBLED317,565$12.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 89% rate it Buy or better
Strong Buy8Buy9Hold2Sell0Strong Sell0
12-month targets · 12 analysts

Price is inside the target range. Median implies +22%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 5, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Oct 16, 2026William Blair
INITIATE
INITIATEOutperform
Sep 21, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 20, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Aug 11, 2026Goldman Sachs
MAINTAIN
MAINTAINNeutral
Aug 6, 2026Wedbush
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$10.0M
sold · 6 insiders
DateInsiderTypeValue
Nov 10, 2026
Nofi Michael
Chief Financial Officer
Nov 10, 2026
SELL$201.8K
Nov 10, 2026
Nofi Michael
Chief Financial Officer
Nov 10, 2026
EXERCISE10,937 sh
Oct 1, 2026
Fox Jonathan C
Director
Oct 1, 2026
AWARD308 sh
Aug 13, 2026
Donovan Joanne M.
CMO
Aug 13, 2026
SELL$126.7K
Aug 12, 2026
KOCH KEVIN
President and CEO
Aug 12, 2026
SELL$361.3K
Aug 12, 2026
MOORE JOHN R
General Counsel
Aug 12, 2026
EXERCISE5,781 sh
Aug 12, 2026
KOCH KEVIN
President and CEO
Aug 12, 2026
SELL$383.3K
Aug 12, 2026
MOORE JOHN R
General Counsel
Aug 12, 2026
SELL$4.4K

Earnings setup

Estimates
−$0.44
EPS estimate, this quarter
−17%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.44-$0.60–-$0.25-15.5%$0.00
Next Q-$0.44-$0.53–-$0.31+18.6%$0.00
Current FY$7.66-$1.50–$9.29+454.7%$0.00
Next FY-$1.89-$2.61–-$1.24-4.0%$8.6M

Short side

FINRA· Oct 30, 2026
12,696,203
shares short
+8.0%
vs prior settlement
9.6
days to cover
≈11.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 10, 2026 Insider
Nofi Michael sold 4,442 shares
Chief Financial Officer @ $45.43 ($201.8K)
Nov 10, 2026 Insider
Nofi Michael acquired via exercise 10,937 shares
Chief Financial Officer
Nov 9, 2026 Other
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
BOULDER, Colo., Nov. 9, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading c
Nov 5, 2026 SEC
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 970,920 shares of Edgewise…
SC 13G/A · Impact 2/10
Oct 1, 2026 Insider
Fox Jonathan C was granted 308 shares
Director
Jun 30, 2026 Inst.
FMR LLC · DOUBLED
5,489,135 shares ($223.0M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
4 drugs tracked · Drug pipeline →
Recent
Nov 9, 2026
Press release
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
BOULDER, Colo., Nov. 9, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical…
Nov 5, 2026
Earnings date
EWTX Q3 2026 Earnings Scheduled · 2026-11-05
Nov 2, 2026
Press release
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., Nov. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage…
Oct 25, 2026
Trial readout
T-90d Trial Readout: Sevasemten Dose 1 (Phase 2)
Trial: A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) Sponsor: Edgewise Therapeutics, Inc. Phase: Phase 2 | Status…
Oct 21, 2026
Trial readout
Results Pending: Sevasemten 10 mg (Phase 2), Completed 44d ago
Trial: Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) Sponsor: Edgewise Therapeutics, Inc. Phase: Phase 2 | Completed…

SecBot reports

14 filings · 2 bullish · 0 bearish · 1 mixed · 11 neutral
All EWTX filing & press-release reports (14)